Michael Beck

18.9k total citations · 1 hit paper
213 papers, 12.2k citations indexed

About

Michael Beck is a scholar working on Physiology, Epidemiology and Rheumatology. According to data from OpenAlex, Michael Beck has authored 213 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 204 papers in Physiology, 92 papers in Epidemiology and 66 papers in Rheumatology. Recurrent topics in Michael Beck's work include Lysosomal Storage Disorders Research (202 papers), Trypanosoma species research and implications (89 papers) and Glycogen Storage Diseases and Myoclonus (64 papers). Michael Beck is often cited by papers focused on Lysosomal Storage Disorders Research (202 papers), Trypanosoma species research and implications (89 papers) and Glycogen Storage Diseases and Myoclonus (64 papers). Michael Beck collaborates with scholars based in Germany, United Kingdom and United States. Michael Beck's co-authors include Atul Mehta, Gere Sunder‐Plassmann, Christoph Kampmann, Catharina Whybra, Roberto Giugliani, Joseph Muenzer, Markus Ries, J. E. Wraith, Andreas Gal and Uma Ramaswami and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Michael Beck

207 papers receiving 11.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

2004 601 citations Atul Mehta, Urs Widmer et al. European Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Michael Beck

Since Specialization

Citations

This map shows the geographic impact of Michael Beck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Beck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Beck more than expected).

Fields of papers citing papers by Michael Beck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Beck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Beck. The network helps show where Michael Beck may publish in the future.

Co-authorship network of co-authors of Michael Beck

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Beck. A scholar is included among the top collaborators of Michael Beck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Beck. Michael Beck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comment: Why are females with Fabry disease affected? 2019 ·Molecular Genetics and Metabolism Reports ·Michael Beck, Timothy M. Cox	15
2	Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS) 2017 ·Orphanet Journal of Rare Diseases ·Joseph Muenzer, Roberto Giugliani, Maurizio Scarpa, Anna Tylki‐Szymańska, (unknown), Michael Beck	54
3	Eight-Year Follow-Up of Neuropsychiatric Symptoms and Brain Structural Changes in Fabry Disease 2015 ·PLoS ONE ·(unknown), (unknown), Julia B. Hennermann, Michael Beck, Andreas Fellgiebel	36
4	Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment 2015 ·Orphanet Journal of Rare Diseases ·Christoph Kampmann, Amandine Perrin, Michael Beck	93
5	The natural history of MPS I: global perspectives from the MPS I Registry 2014 ·Genetics in Medicine ·Michael Beck, Pamela Arn, Roberto Giugliani, Joseph Muenzer, Torayuki Okuyama, J. Michael Taylor, Shari Fallet	118
6	Natural history of alpha mannosidosis a longitudinal study 2013 ·Orphanet Journal of Rare Diseases ·Michael Beck, (unknown), J. E. Wraith, J Zeman, Jean‐Claude Michalski, Paul Säftig, J. Fogh, Dag Malm	44
7	Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey 2011 ·Genetics in Medicine ·Joseph Muenzer, Michael Beck, Roberto Giugliani, Yasuyuki Suzuki, Anna Tylki‐Szymańska, Vassili Valayannopoulos, Ashok Vellodi, J. E. Wraith	77
8	Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase 2010 ·Journal of Pediatric Rehabilitation Medicine ·Celeste Decker, Zi‐Fan Yu, Roberto Giugliani, Ida Vanessa Döederlein Schwartz, Nathalie Guffon, Elisa Leão Teles, Clara Sá-Miranda, J. E. Wraith, Michael Beck, Laila Arash, Maurizio Scarpa, David Ketteridge, John J. Hopwood, Barbara Plecko, Robert D. Steiner, Chester B. Whitley, Paige Kaplan, Stuart J. Swiedler, Susan E. Conrad, Paul Harmatz	52
9	Neuropsychiatric symptoms and brain structural alterations in Fabry disease 2010 ·European Journal of Neurology ·Ingrid Schermuly, Matthias J. Müller, (unknown), (unknown), Isabel Keller, Igor Yakushev, Michael Beck, Andreas Fellgiebel	43
10	Evaluation of disease severity in mucopolysaccharidoses 2010 ·Journal of Pediatric Rehabilitation Medicine ·Michael Beck, Joseph Muenzer, Maurizio Scarpa	20
11	Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease 2009 ·SHILAP Revista de lepidopterología ·Michael Beck	1
12	Agalsidase Alfa and Kidney Dysfunction in Fabry Disease 2009 ·Journal of the American Society of Nephrology ·Michael L. West, Kathy Nicholls, Atul Mehta, Joe T.R. Clarke, Robert D. Steiner, Michael Beck, Bruce A. Barshop, William J. Rhead, (unknown), Markus Ries, Raphael Schiffmann	119
13	Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase 2008 ·Molecular Genetics and Metabolism ·Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz, Nathalie Guffon, Elisa Leão Teles, Clara Sá-Miranda, J. E. Wraith, Michael Beck, Laila Arash, Maurizio Scarpa, David Ketteridge, John J. Hopwood, Barbara Plecko, Robert D. Steiner, Chester B. Whitley, Paige Kaplan, (unknown), Stuart J. Swiedler, Celeste Decker	159
14	A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) 2006 ·Genetics in Medicine ·Joseph Muenzer, J. E. Wraith, Michael Beck, Roberto Giugliani, Paul Harmatz, Christine M. Eng, Ashok Vellodi, Rick Martin, Uma Ramaswami, Müge Güçsavaş‐Çalıkoğlu, Suresh Vijayaraghavan, S. Wendt, (unknown), (unknown), Marwan Shinawi, Maureen Cleary, (unknown), (unknown), Alan Kimura	457
15	Anemia is a new complication in Fabry disease: Data from the Fabry Outcome Survey 2005 ·Kidney International ·(unknown), F. Dehout, Andreas Schwarting, A. García de Lorenzo, Roberta Ricci, Christoph Kampmann, Michael Beck, Uma Ramaswami, Aleš Linhart, Andreas Gal, Gunnar Houge, Urs Widmer, Atul Mehta, Gere Sunder‐Plassmann	25
16	Fabry disease: overall effects of agalsidase alfa treatment 2004 ·European Journal of Clinical Investigation ·Michael Beck, Riccardo Ricci, U. Widmer, F. Dehout, A. García de Lorenzo, Christoph Kampmann, Aleš Linhart, Gere Sunder‐Plassmann, Gunnar Houge, Uma Ramaswami, Andreas Gal, A Mehta	171
17	Anderson-Fabry Disease in Children and Adolescents 2001 ·Contributions to nephrology ·Michael Beck, Catharina Whybra, (unknown), Andrew E. Gal, Markus Ries	7
18	Molecular analysis of Gaucher disease: distribution of eight mutations and the complete gene deletion in 27 patients from Germany 1997 ·Human Genetics ·Philipp le Coutre, Anna Demina, Ernest Beutler, Michael Beck, Petro E. Petrides	22
19	Identification of 16 sulfamidase gene mutations including the common R74C in patients with mucopolysaccharidosis type IIIA (Sanfilippo A) 1997 ·Human Mutation ·Susanna Bunge, Hüseyin İnce, Cordula Steglich, (unknown), Michael Beck, Jacek Zaremba, Otto P. van Diggelen, Birgit Weber, (unknown), Andreas Gal	51
20	Molecular analysis in patients with mucopolysaccharidosis type II suggests that DXS466 maps within the Hunter gene 1993 ·Human Genetics ·Cordula Steglich, Susanna Bunge, Theo J.M. Hulsebos, Michael Beck, (unknown), E. Schwinger, (unknown), (unknown)	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact